NASDAQ:REGN Regeneron Pharmaceuticals (REGN) Stock Price, News & Analysis → Nvidia’s Quiet $1 Trillion Pivot (From Weiss Ratings) (Ad) Free REGN Stock Alerts $1,001.73 -1.22 (-0.12%) (As of 04:31 PM ET) Add Compare Share Share Today's Range$992.22▼$1,002.9550-Day Range$883.20▼$1,005.8752-Week Range$684.80▼$1,016.00Volume248,899 shsAverage Volume472,398 shsMarket Capitalization$110.38 billionP/E Ratio29.59Dividend YieldN/APrice Target$989.86 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Regeneron Pharmaceuticals alerts: Email Address Regeneron Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.76 Rating ScoreUpside/Downside1.0% Downside$989.86 Price TargetShort InterestHealthy1.48% of Shares Sold ShortDividend StrengthN/ASustainability-2.69Upright™ Environmental ScoreNews Sentiment0.66Based on 20 Articles This WeekInsider TradingSelling Shares$55.15 M Sold Last QuarterProj. Earnings Growth8.70%From $37.23 to $40.47 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.02 out of 5 starsMedical Sector182nd out of 904 stocksPharmaceutical Preparations Industry75th out of 427 stocks 2.4 Analyst's Opinion Consensus RatingRegeneron Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.76, and is based on 15 buy ratings, 4 hold ratings, and 1 sell rating.Amount of Analyst CoverageRegeneron Pharmaceuticals has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Regeneron Pharmaceuticals' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.48% of the outstanding shares of Regeneron Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverRegeneron Pharmaceuticals has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Regeneron Pharmaceuticals has recently increased by 3.82%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldRegeneron Pharmaceuticals does not currently pay a dividend.Dividend GrowthRegeneron Pharmaceuticals does not have a long track record of dividend growth. Previous Next 2.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRegeneron Pharmaceuticals has received a 8.96% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Aflibercept", "Casirivimab and imdevimab", and "Alirocumab" products. See details.Environmental SustainabilityThe Environmental Impact score for Regeneron Pharmaceuticals is -2.69. Previous Next 3.1 News and Social Media Coverage News SentimentRegeneron Pharmaceuticals has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 20 news articles for Regeneron Pharmaceuticals this week, compared to 15 articles on an average week.Search Interest11 people have searched for REGN on MarketBeat in the last 30 days. This is an increase of 10% compared to the previous 30 days.MarketBeat Follows11 people have added Regeneron Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 10% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Regeneron Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $55,145,791.00 in company stock.Percentage Held by InsidersOnly 7.48% of the stock of Regeneron Pharmaceuticals is held by insiders.Percentage Held by Institutions83.31% of the stock of Regeneron Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Regeneron Pharmaceuticals' insider trading history. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Regeneron Pharmaceuticals are expected to grow by 8.70% in the coming year, from $37.23 to $40.47 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Regeneron Pharmaceuticals is 29.53, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 135.53.Price to Earnings Ratio vs. SectorThe P/E ratio of Regeneron Pharmaceuticals is 29.53, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 132.79.Price to Earnings Growth RatioRegeneron Pharmaceuticals has a PEG Ratio of 2.07. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioRegeneron Pharmaceuticals has a P/B Ratio of 4.22. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Regeneron Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad The Freeport SocietyBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend into chaos.Click here now to see my urgent election warning. About Regeneron Pharmaceuticals Stock (NASDAQ:REGN)Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.Read More REGN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart REGN Stock News HeadlinesJune 8 at 8:30 AM | insidertrades.comBonnie L. Bassler Sells 827 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) StockMay 30, 2024 | insidertrades.comMichael S. Brown Sells 1,172 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) StockMay 18, 2024 | insidertrades.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) CEO Leonard S. Schleifer Sells 22,830 SharesMay 17, 2024 | insidertrades.comLeonard S. Schleifer Sells 25,000 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) StockMay 10, 2024 | marketbeat.comWill the Biotech Sector Shift From Lagger to Leader?The biotech sector and its popular ETF, the iShares Biotechnology ETF NASDAQ: IBB, have lagged the overall market during the year, with its shares slightly red. However, in recent weeks, the sector has enjoyed a significant rally after bouncing off its uptrend support and now consolidating near several major Simple Moving Averages (SMA).May 10, 2024 | marketbeat.comWill the Biotech Sector Shift From Lagger to Leader? (REGN)The biotech sector has experienced a significant rally after bouncing off uptrend support and is now consolidating near major SMAs.June 8 at 9:04 AM | americanbankingnews.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Director Bonnie L. Bassler Sells 827 Shares of StockJune 7 at 10:10 AM | fool.comStock Split Watch: 3 Growth Stocks That Could Be NextJune 6, 2024 | americanbankingnews.comRegeneron Pharmaceuticals (NASDAQ:REGN) PT Raised to $1,200.00June 5, 2024 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGNJune 5, 2024 | seekingalpha.comRegeneron Pharmaceuticals, Inc. (REGN) Management presents at Jefferies 2024 Global Healthcare Conference (Transcript)June 3, 2024 | insidermonkey.comIs Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) the Best Bet in Gene Therapy Industry?June 2, 2024 | americanbankingnews.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Average Rating of "Moderate Buy" by BrokeragesMay 31, 2024 | globenewswire.comPress Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPDMay 31, 2024 | globenewswire.comDupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPDMay 31, 2024 | globenewswire.comPress Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammationMay 31, 2024 | globenewswire.comUpdate on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 InflammationMay 30, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGNMay 29, 2024 | prnewswire.comBiohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial TumorsMay 25, 2024 | fool.com2 Biotech Stocks to Buy in MayMay 23, 2024 | globenewswire.comPromising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCOMay 23, 2024 | businesswire.comMary Kay Awards Grants to Five Aspiring Young Scientists at Regeneron International Science and Engineering FairMay 23, 2024 | fool.com3 Stocks That Have Turned $25,000 Into More Than $1 Million in 15 YearsMay 22, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGNMay 22, 2024 | finance.yahoo.comIs Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Trading At A 48% Discount?See More Headlines Receive REGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/02/2024Today6/10/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:REGN CUSIP75886F10 CIK872589 Webwww.regeneron.com Phone(914) 847-7000Fax914-347-2113Employees13,450Year Founded1988Price Target and Rating Average Stock Price Target$989.86 High Stock Price Target$1,200.00 Low Stock Price Target$720.00 Potential Upside/Downside-0.5%Consensus RatingModerate Buy Rating Score (0-4)2.76 Research Coverage21 Analysts Profitability EPS (Most Recent Fiscal Year)$33.85 Trailing P/E Ratio29.40 Forward P/E Ratio26.73 P/E Growth2.07Net Income$3.95 billion Net Margins29.45% Pretax Margin30.85% Return on Equity16.83% Return on Assets13.16% Debt Debt-to-Equity Ratio0.10 Current Ratio5.27 Quick Ratio4.51 Sales & Book Value Annual Sales$13.12 billion Price / Sales8.36 Cash Flow$42.93 per share Price / Cash Flow23.18 Book Value$236.63 per share Price / Book4.21Miscellaneous Outstanding Shares110,190,000Free Float101,944,000Market Cap$109.65 billion OptionableOptionable Beta0.13 Social Links Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesDr. Leonard S. Schleifer M.D. (Age 71)Ph.D., Co-Founder, President, CEO & Co-Chairman Comp: $8.18MDr. George D. Yancopoulos M.D. (Age 64)Ph.D., Co-Founder, President, Chief Scientific Officer & Co-Chairman Comp: $7.76MDr. Andrew J. Murphy Ph.D. (Age 65)Executive Vice President of Research Comp: $1.68MMr. Daniel P. Van Plew (Age 51)Executive VP and GM of Industrial Operations & Product Supply Comp: $2.01MMr. Christopher R. Fenimore CPA (Age 53)Senior VP of Finance & CFO Ms. Patrice GiloolySenior Vice President of Quality Assurance & OperationsMr. Bob McCowanSenior VP of IT & Chief Information OfficerMr. Ryan CroweSenior Vice President of Investor Relations & Strategic AnalysisMr. Joseph J. LaRosa (Age 65)Executive VP, General Counsel & Secretary Comp: $1.75MMs. Melissa LoznerSenior VP & Chief Compliance OfficerMore ExecutivesKey CompetitorsAllerganNYSE:AGNAmgenNASDAQ:AMGNVertex PharmaceuticalsNASDAQ:VRTXGilead SciencesNASDAQ:GILDAlexion PharmaceuticalsNASDAQ:ALXNView All CompetitorsInsiders & InstitutionsHamilton Wealth LLCBought 193 shares on 6/10/2024Ownership: 0.000%Railway Pension Investments LtdBought 400 shares on 6/7/2024Ownership: 0.026%Leonard S SchleiferSold 787 sharesTotal: $798,820.74 ($1,015.02/share)Westwood Holdings Group Inc.Sold 266 shares on 6/6/2024Ownership: 0.011%Bonnie L BasslerSold 827 sharesTotal: $836,097.00 ($1,011.00/share)View All Insider TransactionsView All Institutional Transactions Should I Buy Regeneron Pharmaceuticals Stock? REGN Pros and Cons Explained Pros Here are some ways that investors could benefit from investing in Regeneron Pharmaceuticals, Inc.: Regeneron Pharmaceuticals has a strong track record of developing innovative drugs, such as Eylea and Dupixent, which have been successful in the market. The company has a diverse pipeline of potential blockbuster drugs in various stages of development, providing opportunities for future revenue growth. Regeneron's stock price has shown consistent growth over the past year, indicating positive investor sentiment and potential for further appreciation. With a solid financial position and healthy balance sheet, Regeneron is well-positioned to fund its research and development efforts for new drug candidates. Regeneron's collaborations with other pharmaceutical companies and research institutions enhance its research capabilities and increase the likelihood of successful drug development. Cons Investors should be bearish about investing in Regeneron Pharmaceuticals, Inc. for these reasons: The biopharmaceutical industry is highly competitive and subject to regulatory challenges, which could impact the company's ability to bring new drugs to market. Regeneron's heavy reliance on a few key products for a significant portion of its revenue poses a risk in case of unexpected market developments or competition. Market volatility and macroeconomic factors can influence the stock price of pharmaceutical companies like Regeneron, leading to potential fluctuations in investment returns. Regeneron's research and development expenses are substantial, and the success of its future drug candidates is not guaranteed, which could affect the company's profitability. Changes in healthcare policies and regulations, both domestically and internationally, may impact the pricing and reimbursement of Regeneron's products, affecting its financial performance. These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Saturday, June 8, 2024. Please send any questions or comments about these Regeneron Pharmaceuticals pros and cons to contact@marketbeat.com. REGN Stock Analysis - Frequently Asked Questions Should I buy or sell Regeneron Pharmaceuticals stock right now? 21 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last twelve months. There are currently 1 sell rating, 4 hold ratings, 15 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" REGN shares. View REGN analyst ratings or view top-rated stocks. What is Regeneron Pharmaceuticals' stock price target for 2024? 21 equities research analysts have issued 12 month price targets for Regeneron Pharmaceuticals' shares. Their REGN share price targets range from $720.00 to $1,200.00. On average, they anticipate the company's stock price to reach $989.86 in the next year. This suggests that the stock has a possible downside of 1.0%. View analysts price targets for REGN or view top-rated stocks among Wall Street analysts. How have REGN shares performed in 2024? Regeneron Pharmaceuticals' stock was trading at $878.29 at the beginning of the year. Since then, REGN shares have increased by 13.8% and is now trading at $999.54. View the best growth stocks for 2024 here. When is Regeneron Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our REGN earnings forecast. How were Regeneron Pharmaceuticals' earnings last quarter? Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced its quarterly earnings data on Thursday, May, 2nd. The biopharmaceutical company reported $7.97 EPS for the quarter, missing the consensus estimate of $8.46 by $0.49. The biopharmaceutical company had revenue of $3.15 billion for the quarter, compared to analysts' expectations of $3.19 billion. Regeneron Pharmaceuticals had a trailing twelve-month return on equity of 16.83% and a net margin of 29.45%. What ETFs hold Regeneron Pharmaceuticals' stock? ETFs with the largest weight of Regeneron Pharmaceuticals (NASDAQ:REGN) stock in their portfolio include iShares Biotechnology ETF (IBB), Invesco Nasdaq Biotechnology ETF (IBBQ), VanEck Biotech ETF (BBH), Invesco Pharmaceuticals ETF (PJP), First Trust US Equity Opportunities ETF (FPX), Tema Oncology ETF (CANC), ProShares Ultra Nasdaq Biotechnology (BIB) and Invesco Biotechnology & Genome ETF (PBE). What is Leonard S. Schleifer's approval rating as Regeneron Pharmaceuticals' CEO? 423 employees have rated Regeneron Pharmaceuticals Chief Executive Officer Leonard S. Schleifer on Glassdoor.com. Leonard S. Schleifer has an approval rating of 87% among the company's employees. What other stocks do shareholders of Regeneron Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Walt Disney (DIS), Micron Technology (MU), Advanced Micro Devices (AMD) and Salesforce (CRM). Who are Regeneron Pharmaceuticals' major shareholders? Regeneron Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (8.14%), Capital World Investors (4.22%), Capital International Investors (2.84%), Price T Rowe Associates Inc. MD (0.82%), Bank of New York Mellon Corp (0.81%) and BNP PARIBAS ASSET MANAGEMENT Holding S.A. (0.37%). Insiders that own company stock include Andrew J Murphy, Arthur F Ryan, Arthur F Ryan, Bonnie L Bassler, Bonnie L Bassler, Christine A Poon, Christopher R Fenimore, George L Sing, George Yancopoulos, Huda Y Zoghbi, Joseph J Larosa, Joseph L Goldstein, Joseph L Goldstein, Leonard S Schleifer, Marc Tessier-Lavigne, Marion Mccourt, Michael S Brown, N Anthony Coles, Neil Stahl, P Roy Vagelos, Plew Daniel P Van, Plew Daniel P Van, Robert E Landry and Robert E Landry. View institutional ownership trends. How do I buy shares of Regeneron Pharmaceuticals? Shares of REGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does Regeneron Pharmaceuticals have any subsidiaries? The following companies are subsidiares of Regeneron Pharmaceuticals: Eastside Campus Holdings LLC, Loop Road Holdings LLC, OSMR Holdings, Old Saw Mill Holdings LLC, Regeneron Assurance Inc., Regeneron Atlantic Holdings, Regeneron Belgium BV, Regeneron Canada Company, Regeneron Capital International B.V., Regeneron Genetics Center LLC, Regeneron GmbH, Regeneron Healthcare Solutions Inc., Regeneron International Holdings LLC, Regeneron International Limited, Regeneron Ireland Designated Activity Company, Regeneron Ireland Holdings Unlimited Company, Regeneron NL B.V., Regeneron Spain S.L.U., Regeneron UK Limited, and Rockwood Road Holdings LLC.Read More This page (NASDAQ:REGN) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersIt's time to ween off Chinese lithium!As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...Smallcaps Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredMoonshot Coins for the Current Crypto RunDid you see bitcoin crossed $70k again? Don't miss the next bull run. Because while Bitcoin and Ethereum s...Crypto 101 Media | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredRSVP: Charles Payne’s Cash Flow WorkshopDid you know you could "cash flow" the stocks in your portfolio? Without selling a single share of stock? ...Unstoppable Prosperity | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regeneron Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Regeneron Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
